Baseline characteristics
Characteristic | Before propensity score matching | After propensity score matching | ||||
Aspirin | Non-aspirin | P value | Aspirin | Non-aspirin | P value | |
Group | Group | Group | Group | |||
No of ops | 141 | 97 | 78 | 78 | ||
No of pts | 128 | 89 | 78 | 78 | ||
Mean age, years | 41.4±10.2 | 36.5±8.7 | <0.001 | 37.5±9.6 | 37.6±8.9 | 0.996 |
Sex | 0.149 | 0.631 | ||||
Male | 73 (51.8) | 41 (42.3) | 39 (50) | 36 (46.2) | ||
Female | 68 (48.2) | 56 (57.7) | 39 (50) | 42 (53.8) | ||
Preop symptoms | 0.052 | 0.051 | ||||
TIA | 62 (44.0) | 34 (35.1) | 37 (47.4) | 26 (33.3) | ||
Stroke | 68 (48.2) | 50 (51.5) | 37 (47.4) | 41 (52.6) | ||
Others | 6 (4.3) | 12 (12.4) | 2 (2.6) | 10 (12.8) | ||
Asymptomatic | 5 (3.5) | 1 (1.9) | 2 (2.6) | 1 (1.3) | ||
Preop mRS score | 0.417 | 0.186 | ||||
0 | 8 (5.7) | 3 (3.1) | 4 (5.1) | 2 (2.6) | ||
1–2 | 127 (90.1) | 87 (89.7) | 73 (93.6) | 71 (91.0) | ||
3 | 6 (4.3) | 7 (7.2) | 1 (1.3) | 5 (6.4) | ||
Medical history | ||||||
Smoking | 28 (19.9) | 10 (10.3) | 0.048 | 11 (14.1) | 10 (12.8) | 0.815 |
Diabetes | 19 (13.5) | 6 (6.2) | 0.071 | 6 (7.7) | 5 (6.4) | 0.754 |
Hypertension | 47 (33.3) | 31 (32.0) | 0.824 | 22 (28.2) | 27 (34.6) | 0.388 |
Hyperlipidaemia | 13 (9.2) | 5 (5.2) | 0.244 | 6 (7.7) | 4 (5.1) | 0.513 |
Suzuki stage | 0.042 | 0.418 | ||||
1 | 1 (0.7) | 2 (2.1) | 1 (1.3) | 2 (2.6) | ||
2 | 9 (6.7) | 6 (6.3) | 5 (6.4) | 5 (6.4) | ||
3 | 38 (28.1) | 29 (30.2) | 24 (30.8) | 23 (29.5) | ||
4 | 42 (31.1) | 36 (37.5) | 26 (33.3) | 25 (32.1) | ||
5 | 31 (23.0) | 23 (24.0) | 18 (23.1) | 23 (29.5) | ||
6 | 14 (10.4) | 0 (0) | 4 (5.1) | 0 (0) | ||
Posterior involvement | 20 (14.8) | 28 (29.2) | 0.008 | 16 (20.5) | 14 (17.9) | 0.685 |
Follow-up bypass patency | 136 (96.5) | 87 (89.7) | 0.035 | 77 (98.7) | 70 (89.7) | 0.016 |
Data are presented as n (%) unless otherwise indicated. The mean values are presented as SDs.
mRS, modified Rankin scale; Ops, operations; Pts, patients; TIA, transient ischaemia attack.